Navigating the Data Stream Consideration of Current Evidence on GLP-1 Receptor Agonists
Upon completion of this activity, please follow the instructions in the “Method of Participation” section below or in the downloaded PDF. A minimum score of 70% is required to ear credit. It is estimated that it will take 2.0 hours to complete this activity.
Content for this activity is based on the live symposium “Navigating the Data Stream: An Expert-Led Journal Club Focused on GLP-1 Receptor Agonist Studies in Type 2 Diabetes,” which was presented as a satellite symposium at ENDO 2012 on Sunday, June 24, 2012, in Houston, Texas.
This monograph and the live symposium were sponsored by The Endocrine Society, developed by the Institute for Medical and Nursing Education, Inc (IMNE), and supported by an educational grant from Novo Nordisk Inc.
This continuing medical education (CME) activity should be of substantial interest to endocrinologists and other healthcare providers who treat individuals with diabetes.
Upon completion of this educational activity, participants will be able to:
- Utilize recent comparative evidence regarding glycemic control efficacy in selecting a glucagon-like peptide-1 receptor agonist (GLP-1 RA) for individualized treatment regimens
- Assess recent data regarding the safety of GLP-1 RAs (eg, cardiovascular risk, cancer risk, pancreatitis)
- Consider nonglycemic effects (eg, blood pressure, lipid levels) of GLP-1 RAs in developing individualized treatment regimens
- Discuss recent evidence regarding weight loss associated with GLP-1 RAs
- Describe effects of GLP-1 RAs on glycemic control across type 2 diabetes mellitus (T2DM) progression, including use in combination with insulin
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Endocrine Society has achieved Accreditation with Commendation.
The Endocrine Society designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Creditsâ„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Method of Participation
To receive a maximum of 2.0 AMA PRA Category 1 Creditsâ„¢ participants must complete an activity evaluation, as well as an answer sheet or posttest achieving a minimum score of 70%. If learners do not achieve a passing score of 70%, they have the option to change their answers and make additional attempts to achieve a passing score.
This enduring material is presented as a print supplement to Endocrine News. To receive a maximum of 2.0 AMA PRA Category 1 Credit(s)™ participants should:
The estimated time to complete this activity, including review of material, is 2.0 hour(s). For questions about the content or obtaining CME credit, please contact The Endocrine Society at: firstname.lastname@example.org.
Last Review Date: November 29, 2012
Activity Release/Expiration Date: January 2013 â€“ January 2014
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to The Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (eg, stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society and IMNE have reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported relevant financial relationships:
Lawrence Blonde, MD, FACP, FACE
Advisory Board Member-Amylin Pharmaceuticals, Inc, Gilead Science, Inc., GlaxoSmithKline, Janssen Pharmaceuticals, Inc., Merck & Co., Inc, Novo Nordisk Inc., sanofi-aventis U.S. LLC, Santarus, Inc; Principal Investigator-Eli Lilly and Company, Novo Nordisk Inc.,
sanofi-aventis U.S. LLC; Speaker-Amylin Pharmaceuticals, Inc, Boehringer Ingelheim, Johnson & Johnson, Merck & Co., Inc, Novo Nordisk Inc., Santarus, Inc; Stock Ownership-Amylin
Pharmaceuticals, Inc, Pfizer Inc.
Vivian A Fonseca, MD, FRCP
Consultant and Speaker-AstraZeneca, Daiichi Sankyo Co., Ltd., Eli Lilly and Company, GlaxoSmithKline, Novo Nordisk Inc., Pamlab, Inc., sanofi-aventis U.S. LLC, TakedaÂ Pharmaceuticals North America, Inc, Xoma; Research Grant Support-Daiichi Sankyo Co., Ltd., Eli Lilly and Company, Halozyme Therapeutics, Novo Nordisk Inc., Pamlab, Inc., Reata Pharmaceuticals Inc, sanofi-aventis U.S. LLC.
Janet B McGill, MD, MA, FACE
Consultant-Novo Nordisk Inc., sanofi-aventis U.S. LLC; Speaker-Eli Lilly and Company
The following faculty reported no relevant financial relationships: Derek LeRoith, MD, PhD, FACP
The following SPC member who planned and/or reviewed content for this activity reported relevant financial relationships:
Anton Luger, MD
Advisory Board Member, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, F. Hoffmann-La Roche Ltd , Ipsen, Merck & Co., Inc, Merck, Sharp & Dome, Novartis AG, Novo Nordisk Inc, Pfizer Inc, Reckitt Benckiser Group plc, Takeda Pharmaceuticals North America, Inc; Research Grant Support, Novo Nordisk Inc,; Speaker, AstraZeneca, Boehringer Ingelheim, Eli Lilly Lilly and Company, Ipsen, Merck & Co., Inc, Merck, Sharp & Dome, Novartis AG, Novo Nordisk Inc, Pfizer Inc, Reckitt Benckiser Group plc, Takeda Pharmaceuticals North America, Inc.
The following SPC member who planned and/or reviewed content for this activity reported no relevant financial relationships: Jeffery Boord, MD, MPH
The following SPC Committee members reported relevant financial relationships:
Benjamin Leder, MD
Consultant, Merck & Co., Inc; Research Grant Support, Amgen Inc, Eli Lilly and Company
Henry Fein, MD
Investigator, Corcept Therapeutics Joel Finkelstein, MD: Research Grant Support, Abbott Laboratories, AstraZeneca, National Institute of Health Anton Luger, MD: Advisory Board Member, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, F. Hoffmann-La Roche Ltd , Ipsen, Merck & Co., Inc, Merck, Â Sharp & Dome, Novartis AG, Novo Nordisk Inc, Pfizer Inc, Reckitt Benckiser Group plc, Takeda Pharmaceuticals North America, Inc; Research Grant Support, Novo Nordisk Inc,; Speaker, AstraZeneca,
Boehringer Ingelheim, Eli Lilly Lilly and Company, Ipsen, Merck & Co., Inc, Merck, Sharp & Dome, Novartis AG, Novo Nordisk Inc, Pfizer Inc, Reckitt Benckiser Group plc, Takeda Pharmaceuticals
North America, Inc.
Nelly Mauras, MD
Advisory Board Member, Pfizer Inc; Consultant, Ipsen, Viropharma; Research Grant Support, AstraZeneca, Genentech, Inc., Medtronic, Inc./Minimed, Novartis AG, Pfizer Inc, Quest Diagnostics Inc.
Andrea Utz, MD, PhD
Advisory Board Member, Corcept Therapeutics, Ipsen
The following SPC members reported no relevant financial relationships: Ann Kearns, MD, PhD; Connie Newman, MD; Pamela Taxel, MD
The following IMNE staff reported no relevant financial relationships other than those listed below:
Kimberly McFarland, PhD
Stock ownership, Pfizer Inc, Proctor & Gamble
Privacy and Confidentiality Statement
The Endocrine Society and IMNE will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society and
IMNE may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of their CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of The Endocrine Society or the Institute for Medical and Nursing Education, Inc.
Statement of Independence
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, The Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of The Endocrine Society’s Special Programs Committee (SPC). The commercial supporters of this activity have no influence over the selection of the faculty or specific presentations.
Use of Professional Judgment
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.
Drugs and Dosages
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Novo Nordisk Inc.